Bipolar Disorder Market

Market Overview:

The 7 major bipolar disorder markets reached a value of US$ 3.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.8 Billion by 2034, exhibiting a growth rate (CAGR) of 1.82% during 2024-2034.

The bipolar disorder market has been comprehensively analyzed in IMARC's new report titled "Bipolar Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bipolar disorder, also known as manic-depressive illness, refers to a mental health condition that causes extreme shifts in mood, energy, and activity levels. It can be classified into several types based on the pattern and severity of symptoms, including bipolar I, bipolar II, cyclothymic, and unspecified bipolar disorder. Individuals may experience episodes of mania or hypomania, during which they feel unusually elated, irritable, or energetic, and engage in impulsive or risky behaviors. They might also go through depressive periods where they feel sad and depressed and lose interest in things they used to enjoy. In some cases, people with bipolar disorder may exhibit psychotic indications like hallucinations or delusions. The diagnosis of the ailment is typically made by a mental health professional, such as a psychiatrist or psychologist, through a comprehensive assessment of the person's symptoms, medical history, and family history. This evaluation may include a physical exam, blood investigations, and psychological tests to rule out other conditions that may cause similar indication.

The increasing cases of neurochemical imbalances, which can cause symptoms of mania or depression, are primarily driving the bipolar disorder market. Furthermore, the rising prevalence of various associated risk factors, such as genetic predisposition, trauma, stress, substance abuse, etc., is also propelling the market growth. In addition to this, the escalating utilization of antipsychotic medications, including olanzapine and risperidone, for managing manic episodes is creating a positive outlook for the market. Moreover, the inflating usage of cognitive-behavioral therapy (CBT) to assist patients in developing coping skills and identifying triggers for their symptoms, which can help them manage their condition more effectively, is also bolstering the market growth. Apart from this, the emerging popularity of electroconvulsive therapy, since it aids in lowering the indications of depression and mania in individuals with bipolar disorder, is acting as another significant growth-inducing factor. Additionally, the introduction of novel imaging technologies, such as functional magnetic resonance imaging (fMRI), for studying the brain and understanding the neural pathways associated with the ailment is expected to drive the bipolar disorder market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the bipolar disorder market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for bipolar disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bipolar disorder market in any manner.

Recent Developments:

• In April 2024, BioXcel Therapeutics, Inc. announced the design of its SERENITY At-Home Phase 3 trial, which will evaluate BXCL501, the company's investigational, proprietary, orally dissolving film formulation of dexmedetomidine, as a potential acute therapy for agitation associated with bipolar disorders or schizophrenia in the home setting. The Company's proposal to perform this trial utilizing a 120 mcg dose is based on comments received from the U.S. FDA following the recently received agency minutes from the Type C conference.
• In April 2024, Vanda Pharmaceuticals, Inc. stated that the United States FDA has approved Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
• In April 2024, NRx Pharmaceuticals, Inc. reported that the company had achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101.

Key Highlights:

• Epidemiological studies have revealed a lifetime prevalence of approximately 1% for bipolar type I in the general population.
• A major cross-sectional investigation of 11 nations discovered the overall lifetime prevalence of bipolar spectrum disorders was 2.4%, with a frequency of 0.6% for bipolar type I and 0.4% for bipolar type II.
• Bipolar disorder affects around 4.4% of individuals in the United States.
• The average age of start for bipolar disorder appears to be in the early twenties, while findings vary between 20-30 years.
• Female adolescents had a higher prevalence of bipolar disorder (3.3%) than male adolescents (2.6%).
• Bipolar disorders had the highest rate of significant impairment among mood disorders, with an estimated 82.9%.

Drugs:

Asenapine (Saphris) is an atypical antipsychotic medication approved by the U.S. Food and Drug Administration to treat acute manic or mixed episodes of bipolar disorder in both adults and children. Asenapine is a tetracyclic medication with antidopaminergic and antiserotonergic properties with a distinct sublingual route of administration.

Brexpiprazole is a chemical discovered by Otsuka and co-developed with Lundbeck. Brexpiprazole's efficacy may be due to a mixture of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, as well as antagonist activity at serotonin 5-HT2A receptors. Brexpiprazole has a high affinity (subnanomolar) for these receptors as well as the noradrenaline alpha1B/2C receptors.

BXCL501 is an investigational, proprietary, orally disintegrating film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. The drug targets an essential mediator of agitation, as well as it has revealed anti-agitation outcomes in various clinical trials that extend to a variety of neuropsychiatric illnesses.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the bipolar disorder market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the bipolar disorder market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current bipolar disorder marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the bipolar disorder market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the bipolar disorder market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the bipolar disorder market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of bipolar disorder across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of bipolar disorder by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of bipolar disorder by gender across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of bipolar disorder by type across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with bipolar disorder across the seven major markets?
• What is the size of the bipolar disorder patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of bipolar disorder?
• What will be the growth rate of patients across the seven major markets?
   

Bipolar Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for bipolar disorder drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bipolar disorder market?
• What are the key regulatory events related to the bipolar disorder market?
• What is the structure of clinical trial landscape by status related to the bipolar disorder market?
• What is the structure of clinical trial landscape by phase related to the bipolar disorder market?
• What is the structure of clinical trial landscape by route of administration related to the bipolar disorder market?